PARPi olaparib for the targeted treatment of metastatic prostate cancer

(Vall d'Hebron Institute of Oncology) Results from the PROfound phase III study open up a new treatment avenue for the more precise and effective treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed with hormonal therapy.